Last updated on December 2018

Study of Pembrolizumab (MK-3475) vs Placebo for Participants With Non-small Cell Lung Cancer After Resection With or Without Standard Adjuvant Therapy (MK-3475-091/KEYNOTE-091)

Brief description of study

In this study, participants with Stage IB/II-IIIA non-small cell lung cancer (NSCLC) who have undergone surgical resection (lobectomy or pneumonectomy) with or without adjuvant chemotherapy will be treated with pembrolizumab or placebo. The primary study hypothesis is that pembrolizumab will provide improved disease-free survival (DFS) versus placebo.

Clinical Study Identifier: NCT02504372

Find a site near you

Start Over


Chiyoda-Ku, Tokyo, Japan
  Connect »

MSD International GmbH

Lucerne 6, Switzerland
  Connect »

Merck Sharp & Dohme Ltd.

Hoddesdon, United Kingdom
  Connect »

Merck Sharp & Dohme

North Ryde, Australia
  Connect »


Seoul, Korea, Republic of
  Connect »

MSD Brasil

Sao Paulo, Brazil
  Connect »

Merck Canada

Kirkland, QC Canada
  Connect »

Recruitment Status: Open

Brief Description Eligibility Contact Research Team

Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.